Peronne

Psoriatic arthritis (PsA) is a type of arthritis that causes joint swelling and stiffness and is often seen in people with the skin condition psoriasis. It results from an overactive immune system attacking healthy tissue. This research aims to describe the long-term use and effectiveness of risankizumab (RZB) compared to other advanced treatments for managing PsA in everyday clinical care. The study is not conducted in the United States but will take place in about 15 countries and include between 900 and 1200 adult participants. Participants will be assigned in a 2 to 1 ratio to receive either risankizumab or other advanced therapeutic agents. The treatments will be given following usual medical guidelines, including approved dosing and indications, as determined by local regulations and professional standards. All study visits will occur during routine clinical care with no extra burden on participants. Participants will be followed and monitored for 24 months to observe treatment persistence. During the study, participants will continue their regular clinical visits without additional procedures or tests required by the study. Researchers will measure how many participants continue their prescribed treatment over the 24-month period. The study focuses on real-world treatment patterns and outcomes in patients with active PsA who have previously shown an inadequate response or intolerance to certain medications. Safety monitoring will align with routine clinical practice throughout the study duration.

This research aims to evaluate the safety and performance of the SYMBOL range of medical devices used in total hip arthroplasty (THA) procedures. It focuses on patients undergoing either primary or revision total hip replacements due to various hip conditions, including degenerative hip joint disease, post-traumatic osteoarthritis, hip arthritis, femoral neck fractures, avascular necrosis of the femoral head, or failure of previous joint implants. The study will follow patients for a period of 10 years to assess long-term outcomes. Participants will receive total hip arthroplasty using at least one medical device from the SYMBOL range. The study monitors the survivorship of 13 individual SYMBOL orthopedic components over the 10 years following surgery. Both primary and revision hip replacement procedures are included, and the devices used are those manufactured by DEDIENNE Santé under the SYMBOL range. During the study, patients will be regularly assessed to monitor the performance and safety of the implanted devices. Researchers will track the longevity of the implants and watch for any complications or failures. Participants must be able to read, write, and understand French and will provide informed consent. The study excludes those unable to follow procedures or who have previously participated with a SYMBOL device. The total duration of participation is 10 years post-operation, allowing comprehensive long-term monitoring.